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EndocytosisInsulin receptor (IR) endocytosis requires a remodelling of the actin cytoskeleton. We show here
that ANXA2 is SUMOylated at the K10 located in a non-consensus SUMOylation motif in the N-term-
inal domain. The Y24F mutation decreased the SUMOylation signal, whereas insulin stimulation
increased ANXA2 SUMOylation. A survey of protein SUMOylation in hepatic Golgi/endosome (G/E)
fractions after insulin injections revealed the presence of a SUMOylation pattern and conﬁrmed
the SUMOylation of ANXA2. The construction of an IR/ANXA2/SUMO network (IRASGEN) in the G/E
context reveals the presence of interacting nodes whereby SUMO1 connects ANXA2 to actin and
microtubule-mediated changes in membrane topology. Heritable variants associated with type 2
diabetes represent 41% of the IRASGEN thus pointing out the physio-pathological importance of this
subnetwork.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the invagination of multivesicular bodies [5,6]. ANXA2 plays anThe functions of annexins are linked to their ability to interact
with cellular membranes in a regulated manner [1–3]. Annexin
A2 (ANXA2), in association with S100A10, was the ﬁrst annexin
shown to be able to bind and bundle actin ﬁlaments in vitro. An
N-terminal sequence (residues 1–30) appears to be involved in
the bundling activity [4]. Despite their ability to bundle actin ﬁla-
ments, imaging studies have shown that annexins are not asso-
ciated with prominent actin bundles and cables such as stress
ﬁbres within cells. Instead, more dynamic actin structures, in par-
ticular those associated with cellular membranes, were noted [4].
In contrast to ANXA1, ANXA2 interacts with cholesterol and actin
[5]. The depletion of ANXA2 with siRNA has shown that it is
involved in the biogenesis of endosomes without interfering withimportant role in early to late endosomal transport by nucleating
and stabilising F-actin, forcing membrane remodelling and thus
endosome biogenesis [5,7,8]. In addition, the activity of ANXA2 at
actin assembly points is regulated by phosphorylation at Y24 at
the N-terminal domain by vSrc [8].
Insulin, in addition to initiating metabolic responses, elicits
major changes in the F-actin distribution [9,10]. Previous reports
have suggested that the tyrosine phosphorylation of ANXA2 at
Y24 is involved in the endocytic trafﬁc of the insulin receptor
(IR) [11,12]. In a recent study, we showed that the SUMOylation
of ANXA1 occurs in the consensus small ubiquitin-related modiﬁer
(SUMO) motif (wKXE/D) located at the C-terminal domain and is
regulated by EGF [13]. We show here that ANXA2 is also
SUMOylated. We identiﬁed a SUMOylatable site in the N-terminal
domain of ANXA2. We also demonstrate that ANXA2 SUMOylation
is regulated by the ligand insulin in cultured cells.
2. Materials and methods
2.1. Cell culture
LNCaP (LNCaP.FGC, ATCC/CRL-1740) cells were maintained in
RPMI 1640 medium (HyClone) containing 10% FBS, 2.05 mM
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cultured at 37 C in a 5% CO2 constant atmosphere. In some experi-
ments (Fig. 3), cells were grown in the absence of FBS for 2 h prior
to insulin stimulation (15 min, 10 ng/ml).
2.2. Cells transfection
Cells were plated 20 h in advance at a 60% conﬂuence. They
were washed once with the culture medium and incubated 24 h
in medium containing the plasmid:Fugene HD (Roche Diagnostics
Canada, Laval, QC) complex (ratio 2 lg DNA:9 ll Fugene HD)
prepared according to the manufacturer’s protocol. The non-
transfected (NT) control was realised using empty vector. Cellular
lysates were solubilised in Laemmli sample buffer and boiled for
5 min.
2.3. Plasmid constructs
Total cellular RNA from mouse ﬁbroblasts (MF WT) was
extracted using TRIzol Reagent (Invitrogen) according to the manu-
facturer’s instructions. Two micrograms of total RNA was used to
synthesise the cDNA using Omniscript reverse transcriptase
(Qiagen). The pEGFP-SUMO-1GG and pEGFP-SUMO-1D plasmids,
expressing enhanced GFP-tagged SUMO-1 coding sequence in its
constitutively active form with a diglycine group at the end
(SUMO-1GG) or an inactive form (G96D) where the glycine group
has been replaced by a stop sequence (SUMO-1D), respectively,
were realised using the complete SUMO1 human coding sequence
ampliﬁed with SUMO-1GG forward primer: 50-GATCTCGAGATGTC
TGACCAGGAGGC-30; SUMO-1GG reverse primer: 50-GCTCTAGAC
TAACCCCCCGTTTGTTCCTG-30; SUMO-1D forward primer: 50-GAT
CTCGAGATGTCTGACCAGGAGGC-30; and SUMO-1D forward
reverse primer: 50-GCTCTAGACTACGTTTGTTCCTG-30. All PCR prod-
ucts were digested with XhoI and XbaI, gel puriﬁed and individu-
ally inserted in pEGFP-C3 vector (BD Bioscience, Mississauga, ON)
at corresponding sites previously treated with the same restriction
enzymes as described previously [13].
The plasmid pcDNA3-N-MYC-ANXA2 coding for ANXA2 was
constructed using the complete mouse coding sequence ampliﬁed
with ANXA2 forward primer: 50-CACGCGGCCGCTCATGTCTACTGT
CCACGAAATCCTG-30; ANXA2 reverse primer: 50-GCTCTAGAT
CAGTCATCCCCACCACACAGG-30. PCR products were digested with
NotI and XbaI, gel puriﬁed and inserted into pcDNA3-N-MYC at
corresponding sites to generate a fusion protein bearing an
N-terminal MYC tag [13].
2.4. Site-directed mutagenesis
Mutagenesis was carried out by polymerase chain reaction
(PCR). The mutations were made in the plasmid template
pcDNA3-N-MYC–ANXA2 using the GeneTailor™ Site-Directed
Mutagenesis System (Invitrogen Life Technology, Carlsbad, CA)
according to the manufacturer’s protocol. Base substitution muta-
genic overlapping oligonucleotide primers corresponded to the
noted position and used the relevant plasmids as template.
2.5. The (G/E) hepatic fractions
Fractions were prepared and characterised based on enzyme
markers, electron microscopy and ligand-mediated endocytosis
as originally described. A proteomic survey of major proteins in
the G/E fraction was also previously reported (666 unique
proteins) [14].2.6. Immunoblots analysis
Antibodies were obtained from various suppliers: anti-MYC
(9E10), anti-IR, anti-p-TYR (PY20) (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-ANXA2 (BD Transduction Laboratories,
Montreal) Anti-GFP (Invitrogen life technology, Carlsbad, CA),
anti-MYC (9E10) (Santa Cruz Biotechnology, Santa Cruz, CA). The
anti-beta actin antibody was from Sigma–Aldrich (St. Louis, Mo).
The anti-SUMO1 antibody was produced in the lab and its proper-
ties previously described [15]. Membranes (PVDF) were revealed
using a chemiluminescence kit (ECL, PerkinElmer Life Science,
Boston, MA). In some experiments (Fig. 3) the signals were anal-
ysed using an ImageQuant LAS 40000 imager (GE Healthcare
Biosciences). All other chemicals were analytical grade and were
purchased from Fisher Scientiﬁc (Sainte-Foy, Québec) or Roche
Laboratories (Laval, Québec).
2.7. Immunoprecipitation (IP)
G/E fractions (200 mg proteins) were solubilised (4COC,
60 min) in the presence of 0.3% Empigen BB and centrifuged at
240000g for 30 min. Supernatants were submitted to immunopre-
cipitation (IP). IPs were performed using the anti-SUMO antibody
covalently coupled to beads (Carbolink, Pierce, Rockford, IL) and
proteins were eluted with 100 mM glycine pH 2.4. The eluates
were immediately neutralised (Tris 1 M, pH 7.5) and submitted
to the immunoblotting analysis.
2.8. Database and network analyses
Functional and physical protein–protein interaction networks
(PPIN) were generated based on a previous protein survey of the
G/E fraction [14]. The PPIs were provided by the STRING database
(ﬁlter set at 0.700) [16] and by the Biological General Repository
Interaction Datasets (BioGRID) [17]. The interactions were visua-
lised on the Cytoscape platform (Version 2.8.2). Self-loops and
duplicated edges were removed prior to the analysis. Cellular com-
ponent grouping and functional analysis were performed after a
gene ontology analysis with the Biological Networks Gene
Ontology tool (BINGO version 2.44) [18,19]. A cluster analysis
helped to discern compact groups of highly interconnected pro-
teins with functional relationships with AnxaA2 with conﬁdence.
This was done with the afﬁnity propagation algorithm, a compo-
nent of the cluster maker plugin implemented in Cytoscape [20].
The analysis for type 2 diabetes common variants content within
IRASGEN was done as previously described [21].3. Results
3.1. SUMOylation of the ANXA2 N-terminal domain
Co-transfections of GFP-tagged SUMO-1 with Mus musculus
MYC-ANXA2 in LNCaP cells [13] revealed the presence of a weak
but consistent 78kDa signal on immunoblots (Fig. 1A). This
78kDa signal is compatible with the presence of a complex com-
posed of one GFP-SUMO-1 molecule (approximately 40kDa)
bound to the MYC-ANXA2 (approximately 38kDa). To further
conﬁrm these results we immunoprecipitated the GFP, and MYC
tagged proteins before immunoblot analysis. The results con-
ﬁrmed enhanced MYC-ANXA2 SUMOylation signal (Fig. 1B) that
was not affected by the K248 mutation located in the C-terminal
VKGD consensus motifs (not shown, K257 for ANXA1 [13]).
Phosphorylation, truncation and mutations within the N-terminal
Fig. 1. SUMOylation of ANXA2 in LNCaP cells. LNCaP cells were co-transfected with EGFP-SUMO-1GG or EGFP-SUMO-1D and mus musculus MYC-ANXA2 constructs. (A)
Immunoblot were realised on whole cell extracts using a-MYC, a-GFP, and a-b-galactosidase. (B) Immunoprecipitation (IP) of SUMOylated ANXA2. LNCaP cells co-transfected
with EGFP-SUMO-1GG and MYC-ANXA2. IPs were done using a-MYC or a-GFP antibodies. Proteins were separated on SDS–PAGE (10% resolving gels) and immunoblotted
using the a-GFP antibody.
Fig. 2. SUMOylation of the ANXA2 N-terminal domain. LNCaP cells were co-
transfected with the EGFP-SUMO-1D or EGFP-SUMO-1GG and with the wild type
construct or constructs bearing the single (K10R or K28R) or double (K10/28R) K
mutations in the N-terminal sequence of mus musculus (Mm) MYC-ANXA2.
Immunoblots were realised using an a-MYC antibody (pieces of the same
membrane). NT = non-transfected cells. Upper panel, MYC-Anxa2S: SUMOylated
form of ANXA2. Higher panel: ANXA2 SUMOylation densitometry, expressed as the
proportion of the control signal (MmA2 plus SUMOGG). The values shown are the
means ± S.D. (⁄P < 0.001, n = 4, two-tailed unpaired Student’s t-tests).
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[22–27]. The fact that SUMO can be conjugated to K residues in
non-consensus motifs [28,29] led us to think that membrane
aggregation properties or other functions might be modulated
by the SUMOylation of N-terminal residues. We reasoned that
if at least one of the two N-terminal K residues (Mm ANXA2
K10R, K28R) is scored, a functional model for ANXA
SUMOylation might be validated. We therefore mutated residues
K10 and K28 of ANXA2. The results conﬁrmed that the presence
of signal at 78kDa was signiﬁcantly decreased by 50% by the
K10R mutation but not the K28R mutation (Fig. 2). We concluded
that K10 in the N-terminal loop of ANXA2 is a major
SUMOylatable site.
3.2. Insulin increases ANXA2 SUMOylation
Phosphorylation of Y- (and S-) residues in the N-terminal region
of annexins regulates their function [2,3,8,22,25,30–34]. ANXA2 is
also a putative substrate for the internalised IR [11]. We thus veri-
ﬁed if ANXA2 SUMOylation is regulated by insulin. We found that
the Y24F mutation in ANXA2 signiﬁcantly decreases the
SUMOylation signal of the 78kDa complex by 60% (Fig. 3A). Cells
cultivated in the absence of serum for 2 h displayed an approxi-
mately 50% lower ANXA2 SUMOylation signal (Fig. 2B). In contrast,
after 15-min insulin stimulation, the IR 95kDa b-subunit autophos-
phorylation increased concurrently with the reappearance of the
SUMOylation signal. For the Y24F mutant, there was no increase
in the SUMO signal (Fig. 3B). Therefore, insulin, presumably
through Y24 tyrosine phosphorylation, markedly inﬂuences the
SUMOylation of ANXA2.
Fig. 3. Stimulation of ANXA2 SUMOylation by insulin in LNCap cells. (A) LNCaP cells
were co-transfected with the EGFP-SUMO-1GG and the wild type construct or a
construct bearing the Y24F mutation in the N-terminal sequence of mus musculus
(Mm) MYC-ANXA2. Densitometry data were normalised for b-tubulin and
expressed as a% of the control (MmA2) value (two-tailed unpaired Student’s t-
tests, n = 4, ⁄P 6 0.001). (B) LNCaP cells were co-transfected with the EGFP-SUMO-
1GG and the wild type mus musculus (Mm) MYC-ANXA2 constructs. Cells were
cultivated in the presence or absence (2 h) of FBS and stimulated with insulin
(10 ng/ml) for 15 min. Immunoblots were realised using an a-MYC, IR a-b-subunit
(95kDa) or a-p-TYR antibody (PY-95kDa, pieces of the same membrane, repre-
sentative of two independent experiments, 7.5% resolving gels). NT = non-trans-
fected cells. MYC-Anxa2S: SUMOylated form of ANXA2.
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To further assess the signiﬁcance of the ANXA2 SUMOylation
modiﬁcation and its regulation by the IR, we veriﬁed the presence
of SUMOylation signals and their responsiveness to insulin in vivo.
To achieve this goal, we used a well-characterised mixed Golgi/
endosome (G/E) fraction isolated from the rat liver [35]. After the
intravenous injection of a single insulin dose, the tyrosine phos-
phorylated IR internalised in the G/E fraction in a time-dependent
manner, as originally reported [35] (Fig. 4A, lower panels). Under
these conditions, protein bands of approximately 40–200kDa
revealed by the anti-SUMO1 antibody appeared at 2 and 15 min
after insulin injections (Fig. 4A, upper panel). Of further interest,
ANXA2 was readily detected in anti-SUMO1 immunocomplexes
prepared following insulin stimulation. The 55kDa doublets are
compatible with the presence of a complex composed of one or
two SUMO-1 molecules (approximately 12kDa) bound to ANXA2
(approximately 38kDa) (Fig. 4B).3.4. Analysis of IR-ANXA2-SUMO interactions in Golgi/endosome
fractions (IRASGEN)
To predict the functions of the ANXA2 SUMOylation process, we
analysed the IR-ANXA2-SUMO connectivity in the G/E context by
using a previous protein survey [14]. We used an afﬁnity prop-
agation plugin set at 25 iterations and implemented in cytoscape
(2.8.2) to generate subnetworks of dense protein complexes. The
network is made up of 202 nodes and 526 edges. Its functional
analysis was performed with the Gene Ontology plugin BINGO ver-
sion 2.44. A ﬁrst dense complex (yellow) is mainly formed of the
different Annexins (ANXA1, ANXA5) and cytoskeletal proteins
(S100a 6, CEACAM, vimentin and the src family kinase Lyn). A sec-
ond dense network is related to the IR connected with elements of
the vATPase involved in proton pumping and the dissociation of
insulin from the IR at acidic lumenal pH [36–38]. Through SUMO
and elements of the ubiquitin machinery (Uba1, Ubb), ANXA2
interacts with elements of the endolysosomal trafﬁcking machin-
ery (Arhgdia and Gdi2, Rab5, Rab7) and with the actin-microtubule
cytoskeleton (RhoA, Kif5A), suggesting that by regulating ANXA2
SUMOylation, the IR controls its own trafﬁc by acting on the local
organisation of actin and microtubules (Fig. 5). Of further interest,
the physiopathological importance of IRASGEN is pointed out by
the fact that common heritable variants associated with type 2 dia-
betes represent 40.9% of the network (Fig. 5, squares) and 72.7% for
the ANXA2 ﬁrst interactors (Fig. 5, yellow squares) including
ANXA2, ANXA1, LYN, S100 and CEACAM1.4. Discussion
The SUMOylation of annexins and the regulation of ANXA1
SUMOylation by EGF in LNCap cells has been reported recently
[13,15]. We found here that SUMO1 can be conjugated within a
non-consensus motif (LCK10LSL) located in the N-terminal domain
of ANXA2. Picard et al. reported the presence of a non-consensus
motif, similar to the one involved here, in which a phosphorylated
S residue replaced the negatively charged D/E residues [39]. The
ﬁnding that ANXA2 SUMOylation is regulated by insulin is also
consistent with previous reports suggesting that the tyrosine phos-
phorylation of ANXA2 is involved in the endocytic trafﬁc of the IR
[11,12].
Fig. 4. Protein SUMOylation in isolated endosomes stimulated with insulin. Rats were injected via the jugular vein with a single dose of insulin (15 lg/100 g body weight).
Endosomes (G/E fraction) were prepared from two livers at each indicated time. Time 0 is buffer alone with immediate sacriﬁce of the animals. Membranes (70 lg proteins)
were subjected to (A) immunoblot analysis with the anti-SUMO-1 (higher panel), anti-IR (95kDa b-subunit), phosphotyrosines (PY-20, IR tyrosine phosphorylation, PY-
95kDa) and the anti-beta actin antibodies. (B) The SUMOylated proteins were immunopuriﬁed from the solubilised G/E fraction (200 lg proteins) isolated 2 min after insulin
injections. The eluted proteins were blotted against the ANXA2 or SUMO1 antibodies.
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where it appears to function by supporting the assembly of mem-
brane lipids and recruiting proteins initiating actin-remodelling
events [12,41]. SUMO1 can add a new dimension by connecting
with Arhgdia, Rhoa and Rabs 5, 7 (Fig. 5). The Rho GTPase family
contains proteins that are involved in the regulation of the actin
cytoskeleton, cellular migration [42,43] and endocytic trafﬁc [44].
Arhgdia itself is a protein that is ubiquitously expressed in tissues
and binds to most of the GTPases, including Rac1, RhoA, and Cdc42.
It can act: (i) by masking the membrane anchoring domain of
GTPases, thereby restricting them to the cytosol; (ii) by blocking
the interaction with guanine nucleotide exchange factors (GEF),
thus inhibiting GTPase activation; and (iii) by blocking binding to
downstream partners [45]. Transgenic mice lacking RhoGDIa pre-
sent intense vacuolisation at the basal side of epithelial cells
[46]. In Dictyostelium species lacking GDI-1, a RHOGDI homologue,
the contractile vacuolar system is severely affected [47]. RhoGDI
can be viewed as a global regulator of Rho-dependant signalling
pathways due to its ability to maintain the equilibrium between
vacuolar transport and apoptosis.
Spatial and temporal regulation of actin polymerisation is criti-
cal for endocytosis [48–50]. Particularly, the endocytic recycling
compartment is a site that integrates vesicular transport with sig-
nalling modules that control actin remodelling [51]. Recyclingendosomes are enriched in lipid microarrays that are involved in
membrane curvature and facilitate actin-regulated signalling
[52]. It was inferred that these domains have a role in the forma-
tion of membrane carriers [53], making the endocytic recycling
compartment a centre that integrates vesicular transport with
the signalling modules that control actin remodelling [54,55]. In
this regard, the IR (a high-recycling receptor) locates in an actin-
dependent manner at the microvilli on the hepatocyte cell surface
[56,57]. The IR has also been observed in caveolin-enriched hepatic
plasma membrane microdomains that rapidly associate with the
actin cytoskeleton in response to insulin [58]. IR autophospho-
rylation is thought to release a constraint that maintains the IR
on the microvilli and allows free, mobile insulin-bound IR to reach
competent membrane environments [59,60]. The link with the
actin network appears to be a key component of IR trafﬁc because
ANXA2 is also linked with the CEACAM1/b-catenin complexes
(Fig. 5) that were shown to be involved in glucose metabolism
and IR regulation [61,62].
ANXA2 was recently implicated in type 2 diabetes and cancers
[63]. High recycling of the IR is important because the liver is also
the main site of insulin clearance [64]. A deﬁciency of hepatic
clearance results in glucose intolerance [65,66]. It is thus possible
that the insulin receptor can control actin-assembly activity
mediated by the SUMOylated ANXA2, which may in turn
Fig. 5. Construction of the endosomal IR/ANXA2/SUMO network (IRASGEN). IRASGEN was constructed from a set of 666 G/E proteins (Bilodeau et al. J. Proteome Res. 2010; 9:
708–717). A link is placed between proteins if there is a functional or physical association between them. Out of the Anxa2 protein complex (nodes in yellow), the node colour
varies with the associated biological process as identiﬁed by the Gene Ontology tool (BINGO) implemented in the visualisation platform Cytoscape. The edge thickness
decreases according to the progression from Anxa2 (red to grey), indicating a functional relationship. Squares correspond to proteins for which the gene was associated with
type 2 diabetes.
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trafﬁcking-related pathophysiological conditions.
ANXA2 was initially identiﬁed as a major substrate of pp60src
and thus has been proposed to play a role in cellular differentia-
tion, cell transformation and cancer [67]. The activity of ANXA2
at actin assembly points is regulated by Y phosphorylation at the
N-terminal domain by pp60src [8]. The fact that the IR and Lyn
are functionally related to ANXA2 (Fig. 5) highlights the idea that
insulin and pp60src signalling are not organised in a linear fashion
but instead rely on densely connected protein interaction net-
works. The particular enrichment of IRASGEN in common heritable
variants further support the idea that the genetic heterogeneity
observed for type diabetes, in lean and obeses subjects, converges
towards few cell biology mechanisms. Further deciphering the
IRASGEN should allow a better understanding of the role of
ANXA2 SUMOylation in complex diseases [68].
Acknowledgements
D.C. and M.B.D. are ﬁrst coauthors. We thank Dr Michael
Schwab for helpful comments and Suzanne Fortier for expert tech-
nical assistance. Work was funded by the Canadian Institutes of
Health Research (CIHR) (RT) and National Sciences and
Enginering Research Council of Canada (NSERC) (RF, NSERCC
Discovery Grant: 155751).
References
[1] Hayes, M.J., Rescher, U., Gerke, V. and Moss, S.E. (2004) Annexin-actin
interactions. Trafﬁc 5, 571–576.
[2] Futter, C.E. andWhite, I.J. (2007) Annexins and endocytosis. Trafﬁc 8, 951–958.[3] Gerke, V. and Moss, S.E. (2002) Annexins: from structure to function. Physiol.
Rev. 82, 331–371.
[4] Santamaria-Kisiel, L., Rintala-Dempsey, A.C. and Shaw, G.S. (2006) Calcium-
dependent and -independent interactions of the S100 protein family. Biochem.
J. 396, 201–214.
[5] Morel, E., Parton, R.G. and Gruenberg, J. (2009) Annexin A2-dependent
polymerization of actin mediates endosome biogenesis. Dev. Cell 16, 445–457.
[6] Hayes, M.J., Shao, D.M., Grieve, A., Levine, T., Bailly, M. and Moss, S.E. (2009)
Annexin A2 at the interface between F-actin and membranes enriched in
phosphatidylinositol 4,5,-bisphosphate. Biochim. Biophys. Acta 1793, 1086–
1095.
[7] Morel, E. and Gruenberg, J. (2009) Annexin A2 binding to endosomes and
functions in endosomal transport are regulated by tyrosine 23
phosphorylation. J. Biol. Chem. 284, 1604–1611.
[8] Hayes, M.J. and Moss, S.E. (2009) Annexin 2 has a dual role as regulator and
effector of v-Src in cell transformation. J. Biol. Chem. 284, 10202–10210.
[9] Moller, N.P., Moller, K.B., Lammers, R., Kharitonenkov, A., Hoppe, E., Wiberg,
F.C., Sures, I. and Ullrich, A. (1995) Selective down-regulation of the insulin
receptor signal by protein-tyrosine phosphatases alpha and epsilon. J. Biol.
Chem. 270, 23126–23131.
[10] Tsakiridis, T., Tong, P., Matthews, B., Tsiani, E., Bilan, P.J., Klip, A. and Downey,
G.P. (1999) Role of the actin cytoskeleton in insulin action. Microsc. Res. Tech.
47, 79–92.
[11] Biener, Y., Feinstein, R., Mayak, M., Kaburagi, Y., Kadowaki, T. and Zick, Y.
(1996) Annexin II is a novel player in insulin signal transduction. Possible
association between annexin II phosphorylation and insulin receptor
internalization. J. Biol. Chem. 271, 29489–29496.
[12] Rescher, U., Ludwig, C., Konietzko, V., Kharitonenkov, A. and Gerke, V. (2008)
Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin
rearrangement and cell adhesion. J. Cell Sci. 121, 2177–2185.
[13] Caron, D., Maarouﬁ, H., Michaud, S., Tanguay, R.M. and Faure, R.L. (2013)
Annexin A1 is regulated by domains cross-talk through post-translational
phosphorylation and SUMOYlation. Cell. Signal. 25, 1962–1969.
[14] Bilodeau, N., Fiset, A., Boulanger, M.C., Bhardwaj, S., Winstall, E., Lavoie, J.N.
and Faure, R.L. (2010) Proteomic analysis of Src family kinases signaling
complexes in Golgi/endosomal fractions using a site-selective anti-
phosphotyrosine antibody: identiﬁcation of LRP1-insulin receptor
complexes. J. Proteome Res. 9, 708–717.
[15] Caron, D., Winstall, E., Inaguma, Y., Michaud, S., Lettre, F., Bourassa, S., Kelly, I.,
Poirier, G.G., Faure, R.L. and Tanguay, R.M. (2008) Proteomic characterization
D. Caron et al. / FEBS Letters 589 (2015) 985–991 991of mouse cytosolic and membrane prostate fractions: high levels of free SUMO
peptides are androgen-regulated. J. Proteome Res. 7, 4492–4499.
[16] Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A.,
Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2013) STRING v9.1: protein–
protein interaction networks, with increased coverage and integration.
Nucleic Acids Res. 41, D808–D815.
[17] Chatr-Aryamontri, A., Breitkreutz, B.J., Oughtred, R., Boucher, L., Heinicke, S.,
Chen, D., Stark, C., Breitkreutz, A., Kolas, N., O’Donnell, L., et al. (2015) The
BioGRID interaction database: 2015 update. Nucleic Acids Res. 43, D470–
D478.
[18] Maere, S., Heymans, K. and Kuiper, M. (2005) BiNGO: a Cytoscape plugin to
assess overrepresentation of gene ontology categories in biological networks.
Bioinformatics 21, 3448–3449.
[19] Saito, R., Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L., Lotia, S., Pico, A.R.,
Bader, G.D. and Ideker, T. (2012) A travel guide to Cytoscape plugins. Nat.
Methods 9, 1069–1076.
[20] Morris, J.H., Apeltsin, L., Newman, A.M., Baumbach, J., Wittkop, T., Su, G., Bader,
G.D. and Ferrin, T.E. (2011) ClusterMaker: a multi-algorithm clustering plugin
for Cytoscape. BMC Bioinformatics 12, 436.
[21] Boutchueng-Djidjou, M., Collard-Simard, G., Fortier, S., Hebert, S.S., Kelly, I.,
Landry, C.R. and Faure, R.L. (2015) The last enzyme of the de novo purine
synthesis pathway ATIC plays a central role in insulin signalling and the Golgi/
endosomes protein network. Mol. Cell. Proteomics. doi: M114.047159, pii:
10.1074/mcp.M114.047159.
[22] Bitto, E. and Cho, W. (1999) Structural determinant of the vesicle aggregation
activity of annexin I. Biochemistry 38, 14094–14100.
[23] Ando, Y., Imamura, S., Hong, Y.M., Owada, M.K., Kakunaga, T. and Kannagi, R.
(1989) Enhancement of calcium sensitivity of lipocortin I in phospholipid
binding induced by limited proteolysis and phosphorylation at the amino
terminus as analyzed by phospholipid afﬁnity column chromatography. J. Biol.
Chem. 264, 6948–6955.
[24] Haigler, H.T., Schlaepfer, D.D. and Burgess, W.H. (1987) Characterization of
lipocortin I and an immunologically unrelated 33-kDa protein as epidermal
growth factor receptor/kinase substrates and phospholipase A2 inhibitors. J.
Biol. Chem. 262, 6921–6930.
[25] Wang, W. and Creutz, C.E. (1994) Role of the amino-terminal domain in
regulating interactions of annexin I with membranes: effects of amino-
terminal truncation and mutagenesis of the phosphorylation sites.
Biochemistry 33, 275–282.
[26] Mishra, R.K., Jatiani, S.S., Kumar, A., Simhadri, V.R., Hosur, R.V. and Mittal, R.
(2004) Dynamin interacts with members of the sumoylation machinery. J.
Biol. Chem. 279, 31445–31454.
[27] Hayes, M.J., Merriﬁeld, C.J., Shao, D., Ayala-Sanmartin, J., Schorey, C.D., Levine,
T.P., Proust, J., Curran, J., Bailly, M. and Moss, S.E. (2004) Annexin 2 binding to
phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is regulated by
the stress response pathway. J. Biol. Chem. 279, 14157–14164.
[28] Matic, I., Schimmel, J., Hendriks, I.A., van Santen, M.A., van de Rijke, F., van
Dam, H., Gnad, F., Mann, M. and Vertegaal, A.C. (2010) Site-speciﬁc
identiﬁcation of SUMO-2 targets in cells reveals an inverted SUMOylation
motif and a hydrophobic cluster SUMOylation motif. Mol. Cell 39, 641–652.
[29] Kjenseth, A., Fykerud, T.A., Sirnes, S., Bruun, J., Kolberg, M., Yohannes, Z.,
Omori, Y., Rivedal, E. and Leithe, E. (2012) The gap junction channel protein
connexin43 is covalently modiﬁed and regulated by SUMOylation. J. Biol.
Chem. doi: M111.281832, pii: 10.1074/jbc.M111.281832.
[30] Zibouche, M., Vincent, M., Illien, F., Gallay, J. and Ayala-Sanmartin, J. (2008)
The N-terminal domain of annexin 2 serves as a secondary binding site during
membrane bridging. J. Biol. Chem. 283, 22121–22127.
[31] Eden, E.R., White, I.J. and Futter, C.E. (2009) Down-regulation of epidermal
growth factor receptor signalling within multivesicular bodies. Biochem. Soc.
Trans. 37, 173–177.
[32] White, I.J., Bailey, L.M., Aghakhani, M.R., Moss, S.E. and Futter, C.E. (2006) EGF
stimulates annexin 1-dependent inward vesiculation in a multivesicular
endosome subpopulation. EMBO J. 25, 1–12.
[33] Varticovski, L., Chahwala, S.B., Whitman, M., Cantley, L., Schindler, D., Chow,
E.P., Sinclair, L.K. and Pepinsky, R.B. (1988) Location of sites in human
lipocortin I that are phosphorylated by protein tyrosine kinases and protein
kinases A and C. Biochemistry 27, 3682–3690.
[34] Schlaepfer, D.D. and Haigler, H.T. (1988) In vitro protein kinase C
phosphorylation sites of placental lipocortin. Biochemistry 27, 4253–4258.
[35] Posner, B.I. and Bergeron, J.J. (2014) Assessment of internalization and
endosomal signaling: studies with insulin and EGF. Methods Enzymol. 535,
293–307.
[36] Doherty, J.Jd., Kay, D.G., Lai, W.H., Posner, B.I. and Bergeron, J.J. (1990)
Selective degradation of insulin within rat liver endosomes. J. Cell Biol. 110,
35–42.
[37] Contreres, J.O., Faure, R., Baquiran, G., Bergeron, J.J. and Posner, B.I. (1998) ATP-
dependent desensitization of insulin binding and tyrosine kinase activity of
the insulin receptor kinase. The role of endosomal acidiﬁcation. J. Biol. Chem.
273, 22007–22013.
[38] Duckworth, W.C., Bennett, R.G. and Hamel, F.G. (1998) Insulin degradation:
progress and potential. Endocr. Rev. 19, 608–624.
[39] Picard, N., Caron, V., Bilodeau, S., Sanchez, M., Mascle, X., Aubry, M. and
Tremblay, A. (2012) Identiﬁcation of estrogen receptor beta as a SUMO-1target reveals a novel phosphorylated sumoylation motif and regulation by
glycogen synthase kinase 3beta. Mol. Cell. Biol. 32, 2709–2721.
[40] Merriﬁeld, C.J., Rescher, U., Almers, W., Proust, J., Gerke, V., Sechi, A.S. and
Moss, S.E. (2001) Annexin 2 has an essential role in actin-based
macropinocytic rocketing. Curr. Biol. 11, 1136–1141.
[41] Martin-Belmonte, F., Gassama, A., Datta, A., Yu, W., Rescher, U., Gerke, V. and
Mostov, K. (2007) PTEN-mediated apical segregation of phosphoinositides
controls epithelial morphogenesis through Cdc42. Cell 128, 383–397.
[42] Coleman, M.L. and Olson, M.F. (2002) Rho GTPase signalling pathways in the
morphological changes associated with apoptosis. Cell Death Differ. 9, 493–
504.
[43] Raftopoulou, M. and Hall, A. (2004) Cell migration: Rho GTPases lead the way.
Dev. Biol. 265, 23–32.
[44] Ellis, S. and Mellor, H. (2000) Regulation of endocytic trafﬁc by rho family
GTPases. Trends Cell Biol. 10, 85–88.
[45] Olofsson, B. (1999) Rho guanine dissociation inhibitors: pivotal molecules in
cellular signalling. Cell. Signal. 11, 545–554.
[46] Togawa, A., Miyoshi, J., Ishizaki, H., Tanaka, M., Takakura, A., Nishioka, H.,
Yoshida, H., Doi, T., Mizoguchi, A., Matsuura, N., et al. (1999) Progressive
impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha.
Oncogene 18, 5373–5380.
[47] Rivero, F., Illenberger, D., Somesh, B.P., Dislich, H., Adam, N. and Meyer, A.K.
(2002) Defects in cytokinesis, actin reorganization and the contractile vacuole
in cells deﬁcient in RhoGDI. EMBO J. 21, 4539–4549.
[48] Welch, M.D. and Mullins, R.D. (2002) Cellular control of actin nucleation.
Annu. Rev. Cell Dev. Biol. 18, 247–288.
[49] Engqvist-Goldstein, A.E. and Drubin, D.G. (2003) Actin assembly and
endocytosis: from yeast to mammals. Annu. Rev. Cell Dev. Biol. 19, 287–332.
[50] Merriﬁeld, C.J., Perrais, D. and Zenisek, D. (2005) Coupling between clathrin-
coated-pit invagination, cortactin recruitment, and membrane scission
observed in live cells. Cell 121, 593–606.
[51] Jones, M.C., Caswell, P.T. and Norman, J.C. (2006) Endocytic recycling
pathways: emerging regulators of cell migration. Curr. Opin. Cell Biol. 18,
549–557.
[52] Grant, B.D. and Donaldson, J.G. (2009) Pathways and mechanisms of endocytic
recycling. Nat. Rev. Mol. Cell Biol. 10, 597–608.
[53] Zimmerberg, J. and Kozlov, M.M. (2006) How proteins produce cellular
membrane curvature. Nat. Rev. Mol. Cell Biol. 7, 9–19.
[54] Chichili, G.R. and Rodgers, W. (2009) Cytoskeleton-membrane interactions in
membrane raft structure. Cell. Mol. Life Sci. 66, 2319–2328.
[55] Saraste, J. and Goud, B. (2007) Functional symmetry of endomembranes. Mol.
Biol. Cell 18, 1430–1436.
[56] Carpentier, J.L. (1993) Robert Feulgen Prize Lecture 1993. The journey of the
insulin receptor into the cell: from cellular biology to pathophysiology.
Histochemistry 100, 169–184.
[57] Lange, K., Brandt, U., Gartzke, J. and Bergmann, J. (1998) Action of insulin on
the surface morphology of hepatocytes: role of phosphatidylinositol 3-kinase
in insulin-induced shape change of microvilli. Exp. Cell Res. 239, 139–151.
[58] Balbis, A., Baquiran, G., Mounier, C. and Posner, B.I. (2004) Effect of insulin on
caveolin-enriched membrane domains in rat liver. J. Biol. Chem. 279, 39348–
39357.
[59] Carpentier, J.L. and McClain, D. (1995) Insulin receptor kinase activation
releases a constraint maintaining the receptor on microvilli. J. Biol. Chem. 270,
5001–5006.
[60] Vainio, S., Heino, S., Mansson, J.E., Fredman, P., Kuismanen, E., Vaarala, O. and
Ikonen, E. (2002) Dynamic association of human insulin receptor with lipid
rafts in cells lacking caveolae. EMBO Rep. 3, 95–100.
[61] Fiset, A., Xu, E., Bergeron, S., Marette, A., Pelletier, G., Siminovitch, K.A., Olivier,
M., Beauchemin, N. and Faure, R.L. (2011) Compartmentalized CDK2 is
connected with SHP-1 and beta-catenin and regulates insulin
internalization. Cell. Signal. 23, 911–919.
[62] Dubois, M.J., Bergeron, S., Kim, H.J., Dombrowski, L., Perreault, M., Fournes, B.,
Faure, R., Olivier, M., Beauchemin, N., Shulman, G.I., et al. (2006) The SHP-1
protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat.
Med. 12, 549–556.
[63] Hayes, M.J., Longbottom, R.E., Evans, M.A. and Moss, S.E. (2007)
Annexinopathies. Subcell. Biochem. 45, 1–28.
[64] Duckworth, W.C., Hamel, F.G. and Peavy, D.E. (1988) Hepatic metabolism of
insulin. Am. J. Med. 85, 71–76.
[65] Abdul-Hay, S.O., Kang, D., McBride, M., Li, L., Zhao, J. and Leissring, M.A. (2011)
Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects
on glucose and insulin tolerance. PLoS One 6, e20818.
[66] Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P.,
Eckman, C.B., Tanzi, R.E., Selkoe, D.J. and Guenette, S. (2003) Insulin-degrading
enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-
amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci.
USA 100, 4162–4167.
[67] Erikson, E. and Erikson, R.L. (1980) Identiﬁcation of a cellular protein substrate
phosphorylated by the avian sarcoma virus-transforming gene product. Cell
21, 829–836.
[68] Sahni, N., Yi, S., Zhong, Q., Jailkhani, N., Charloteaux, B., Cusick, M.E. and Vidal,
M. (2013) Edgotype: a fundamental link between genotype and phenotype.
Curr. Opin. Genet. Dev. 23, 649–657.
